Global Biotechnology Market Grows as Demand for Immunotherapy Cancer Treatment Increases

NEW YORK, September 7, 2018 /PRNewswire/ --

Data compiled by Grand View Research indicates that the global biotechnology market is expected to reach USD 727.1 Billion by 2025. The technological advancement of regenerative therapies is one of the main factors that drive the market growth during the forecast years. The cancer immunotherapy segment is expected to witness a strong growth within the biotechnology industry due to the growing number of deaths occurring due to cancer. Demand for cancer immunotherapy continues to increase as the therapy is proven to have a higher success and efficiency over conventional treatment methods for cancer. According to another report from Transparency Market Research, the global cancer immunotherapy market is expected to achieve USD 124.88 Billion by 2024 while growing at a compound annual growth rate (CAGR) of 14.6%. Regen BioPharma, Inc. (OTC: RGBP), Novavax, Inc. (NASDAQ: NVAX), Adamis Pharmaceuticals Corporation (NASDAQ: NVAX), Palatin Technologies, Inc. (NYSE: PTN), Synergy Pharmaceutical Inc. (NASDAQ: SGYP)

The growing number of clinical trials that are being conducted in immunotherapy is anticipated to fuel the growth of the cancer immunotherapy market. The market is segmented into colorectal cancer, lung cancer, breast cancer, melanoma, prostate cancer, and blood cancer. Based on therapy types, the market can be divided into immune system modulators, immune checkpoint inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. Monoclonal antibodies method has a leading market share, while demand for immune checkpoint inhibitors is expected to increase rapidly.

Regen BioPharma, Inc. (OTCQB: RGBP) announced breaking news after the close that it, "has filed a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate NR2F6 ("Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans").

As previously noted by the Company, NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Based upon the Company's screening programs for treating autoimmune diseases such as Lupus, the data gathered provided support for the filing of this patent application.

Additionally, the Company is moving forward with its NR2F6 antagonist small molecule program designed to unleash the cancer-killing potential of a patient's own immune system."

"The patent application lists molecules that activate NR2F6. As we continue to develop our small molecule program, we learn more about the molecular structures key to activating NR2F6 and develop more optimized compounds," said Harry Lander, Ph.D., President and Chief Scientific Officer of Regen. "Thus, we continue to file for patent protection for these unique molecules."

David Koos, Ph.D., CEO of Regen BioPharma, Inc., added, "We continue to ensure the intellectual property that is generated by Regen is protected so that our shareholders can materially benefit from the commercialization of this technology."

Novavax, Inc. (NASDAQ: NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Novavax, Inc. recently announced it has reached a significant milestone in the Prepare™ Phase 3 clinical trial of its respiratory syncytial virus F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization. Enrollment has reached approximately 4,600 participants, of whom, at least 3,000 have received the RSV F Vaccine. "Reaching this enrollment target for the Prepare trial is a significant milestone in the advancement of our RSV F Vaccine franchise," said Stanley C. Erck, President and Chief Executive Officer of Novavax, Inc. "RSV remains an urgent global unmet medical need due to the mortality and morbidity associated with RSV disease in infants and the absence of a vaccine to prevent such disease. We look forward to completing the interim analysis of the Prepare trial as this is the next step on the path to filing marketing applications in the U.S. and Europe for the first-ever RSV vaccine."

Adamis Pharmaceuticals Corporation (NASDAQ: NVAX) is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. Adamis Pharmaceuticals Corporation recently announced that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc., a division of the Novartis Group, to commercialize Adamis' Symjepi™ product for the emergency treatment of allergic reactions (Type I) including anaphylaxis. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis, stated, "We are very excited about our collaboration with Sandoz. They are among the top pharmaceutical companies in the world and we believe they have the commercial presence and proven track record to maximize the value of Symjepi. We believe the financial terms of this agreement have the potential to bring meaningful recurring revenue to Adamis and we look forward to growing, and possibly expanding, this partnership with Sandoz based on the future success of Symjepi in the market."

Palatin Technologies, Inc. (NYSE: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases and conditions with significant unmet medical need and commercial potential. The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted the bremelanotide New Drug Application (NDA) for filing. The NDA was filed on March 23^rd, 2018 by AMAG Pharmaceuticals, the Company's exclusive North American licensee. Bremelanotide, an investigational melanocortin agonist, is being developed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. "We are very pleased with the FDA's acceptance of the NDA filing for bremelanotide," said Carl Spana, Ph.D., Chief Executive Officer and President of Palatin. "This is an important milestone for Palatin and reflects our drive and commitment to the development of novel therapies to treat conditions with significant unmet medical need and commercial potential. We look forward to assisting AMAG during the FDA review process. HSDD is an underserved medical condition and, if approved, bremelanotide has significant potential as an as-desired treatment of HSDD in premenopausal women."

Synergy Pharmaceutical Inc. (NASDAQ: SGYP) is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. Synergy Pharmaceuticals Inc. recently announced that the Company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong, providing Luoxin exclusive rights to develop and commercialize Synergy's lead product TRULANCE® (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in mainland China, Hong Kong and Macau. "Luoxin is a leading pharmaceutical company in China with strong capabilities for successfully delivering TRULANCE to patients in its market," said Troy Hamilton, Chief Executive Officer of Synergy Pharmaceuticals Inc.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For regen biopharma, Inc. financial news dissemination and pr services, FinancialBuzz.com expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:
[email protected]
+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com